CymaBay Therapeutics

CymaBay has previously announced positive data from its Phase 2 study of seladelpar in patients with PBC and following successful discussion with the FDA and EMA has advanced into a global Phase 3 registration program. CymaBay is committed to bring this program to successful global approvals and to retain full global rights to launch and commercialize seladelpar for the treatment of PBC. In addition, the unmet medical need and the significant market size of NASH represents a unique opportunity for CymaBay. The Company commenced a Phase 2b Proof of Concept Study in 2018.